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Inhaled corticosteroidsAbstract Introduction: Voice changes are not a direct symptom of chronic obstructive pulmonary
disease (COPD), but many COPD patients experience voice changes.
Aim of the work: The aim of this work was to establish the voice changes in patients with chronic
obstructive pulmonary disease.
Patients and methods: Fifty COPD patients were conducted in this study. Patients were enrolled
after obtaining informed consents. All patients were subjected to clinical diagnostic aids which
include history taking (age, sex, smoking index and drug history), general and chest examinations,
spirometry, arterial blood gases, chest X-ray, endoscopic examination of the larynx, auditory per-
ceptual assessment and acoustic analysis of voice.
Results: The age of the patients ranged from 32 to 76 years, all patients were current or former
smokers and the pack year index ranged from 20 to 66 with a mean ± SD value of 41.16 ± 13.80.
Dysphonia was perceived in 25 (50%) patients. There was signiﬁcant positive correlation between
the smoking index with Jitter%, Shimmer% and the grade of dysphonia. There was signiﬁcant posi-
tive correlation between Jitter%, Shimmer% and the grade of dysphonia with the large doses of
ICSs usage and with pMDIs usage. Moreover, there was signiﬁcant inverse correlation between Jit-
ter%, Shimmer% and the grade of dysphonia with DPIs usage and with FVC, FEV1 and MMEF%
of predicted values.
In conclusion: Dysphonia (hoarseness) in COPD patients is multifactorial. Successful analysis
should depend on cooperation between pulmonologists, voice specialists, and laryngologists.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) impacts life in
many ways. Frequent wheezing and coughing, trouble breath-
ing, coughing up mucus and shortness of breath are just a few
COPD symptoms. According to the American Speech-Lan-
guage-Hearing Association, these and other COPD symptoms
can cause havoc on the throat and vocal cords, causing
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Voice changes are not a direct symptom of COPD, but many
COPD patients experience voice changes due to COPD symp-
toms and even certain COPD medications [1].
Hoarseness is an abnormal deep, harsh voice. It can be de-
scribed as raspy, breathy, soft, tremulous and even croaky or
frog-like. Hoarseness may cause pain or a strained feeling
when trying to speak normally. A hoarse voice can be caused
by anything that interferes with the normal vibration of the vo-
cal cords, such as swelling or inﬂammation [2].
The most common cause of hoarseness in an individual
without COPD is acute laryngitis caused by an upper respira-
tory tract infection. Less common causes for those without
COPD are misuse of the voice (such as from yelling or impro-
per singing technique) and cold or ﬂu [3].
For those with COPD, hoarseness may be caused by cold,
ﬂu or a COPD spell, but it may also result from certain COPD
medications. Long-term use of inhaled corticosteroids, a cate-
gory of inhalers used for COPD, and anti-cholinergics is
known to cause hoarseness. Hoarseness is also associated with
smoking tobacco [2].
The initiation of sound and voice begins with inhalation
and exhalation. Thoracic and pulmonary disorders may serve
to limit vital capacity, which in turn will limit breath support
and control necessary for efﬁcient speaking [3,4].
Appropriate prevention of controllable diseases such as
COPD through early smoking cessation and early intervention
for patients that develop these diseases will play a role in main-
taining vocal strength and efﬁciency [5–7].
Dysphonia has been reported in 5–50% of patients using
inhaled steroids. The wide range in this prevalence is a reﬂec-
tion of the means by which these data are calculated (i.e., as
a coincidental ﬁnding in many studies that have ultimately
set out to investigate a different, although associated,
problem). It is also interesting that many studies use the terms
dysphonia and hoarseness as different phenomena when, in
fact, the difference is very subtle. Furthermore, it is apparent
that dysphonia (or hoarseness) usually has been assessed
only by questionnaires rather than by any clinical measure-
ment [7–9].
A dose-dependent hoarseness has been reported in 34% of
patients treated with beclomethasone dipropionate (BDP) or
budesonide (BUD) when both inhaled corticosteroids (ICSs)
were administered via pressurized metered-dose inhalers
(pMDIs) [10]. Other studies have reported an increased risk
of hoarseness with the use of ﬂuticasone propionate compared
to BDP, and with pMDIs compared to dry powder inhalers
(DPIs). It has been suggested that the etiology of dysphonia
in some cases is due to a steroid myopathy affecting the vocal
cord muscles. A closer examination using ﬂexible laryngoscopy
and videostroboscopy reveals varying degrees of myopathy in
symptomatic patients. This problem can, however, be reversed
when therapy with the inhaled steroid is stopped [11–14]. In
contrast, Shaw and Edmunds [15] found that dysphonia not
to be a problem when using regular inhaled BDP 100–
1500 lg per day although no objective measure of dysphonia
was used in this group. A comparable incidence of hoarseness
was established in healthy control subjects and patients receiv-
ing long-term BUD therapy via turbuhaler [16].
Cough is an essential symptom of asthma and in COPD
and has been correlated with worse control. The occurrence
of cough during inhalation has been observed in more thanone third of the patients treated with ICSs [5]. It has been pro-
posed that this side effect occurs as a result of a toxic role of
inhaled excipients (oleicacid) from pMDIs, and from nonspe-
ciﬁc irritant effects of ICSs [17].
Increased dose frequency is known to positively correlate
with the incidence of local side effects [12,17,18]. Twice-daily
regimens reduced the risk of dysphonia and candidiasis
compared with administration four times per day. Once-daily
use of BUD delivered via a turbuhaler is practically free from
local side effects in patients starting to receive this treatment
[18].
Aim of the work
The aim of this work was to establish the voice changes in pa-
tients with chronic obstructive pulmonary disease.
Subjects
Fifty adults with chronic obstructive lung disease were con-
ducted in this study. Patients were admitted to the chest
department, Alexandria University hospital and were enrolled
after obtaining informed consents.
Methods
All patients were conducted to the following protocol:
(1) Clinical diagnostic aids include history taking (age, sex,
smoking index and drug history), local chest examina-
tion and general examination:
(a) Local examination: To conﬁrm the disease.
 To exclude other chest diseases and
exacerbation.(b) General examination:
 To exclude other organ involvement.
 To exclude co-morbidities (gastro esophageal
reﬂux disease and sinusitis).
 To assess complications.(2) Arterial blood gases: using Nova biomedical (Phox S/N:
UO/A 98010). USA measured the following parameters:
 Arterial PH.
 Arterial oxygen tension (PaO2).
 Arterial carbon dioxide tension (PaCo2).
 Oxygen saturation (SaO2).
 Level of serum bicarbonate (Hco3) in mEq/L.(3) Spirometry: all patients underwent standard spirometry
performed by trained personal. Techniques were carried
out according to American Thoracic Society/European
Respiratory Society standards [19].
(4) Plain chest X-ray P-A view.
(5) ENT examination and endoscopic examination of the
larynx in order to assess any vocal fold pathology.
(6) Aerodynamic measurements to assess the vital capacity
and maximum phonation time for calculation of
Phonatory Quotient.
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interview and auditory perceptual assessment of the
patient’s sample voice in order to assess the grade of dys-
phonia by using auditory perceptual assessment (APA):
after careful listening to the patient’s voice by three
phoniatricians, any deviation of normal voice (i.e. dys-
phonia) was noted and reported in each group according
to the following protocol of assessment: (modiﬁed
GRBAS scale, Kotby, 1986) [20]Overall grade: (0) nor-
mal (1) slight (2) moderate (3) severeTabl
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Figure 1 Bilateral hyperaemia and inﬂammation of the vocal
folds. Character (quality): strained–leaky–breathy–rough
(irregular).
 Pitch: increase–decrease-diplophonia.
 Register: habitual register-modal-falsetto-tendency
of vocal fry at the end of phrase-register break.
 Loudness: excessively loud-soft-ﬂuctuating.
 Glottal attack: normal–soft–hard.
 Associated laryngeal functions: cough-whisper.(8) Additional instrumental procedures include acoustic
analysis of the patient’s voice to assess the fundamental
frequency (average F0), jitter%, shimmer%, N/H ratio.
Statistical analysis
Statistical analysis was performed with Sigma Stat 2.0 (Systat
Software Inc., Point Richmond, Calif) and SPSS 14 (SPSS,
Chicago, Ill) for Windows.
Results
This study was carried on 50 COPD patients, 46 males (92%)
and 4 females (8%) their age ranged from 32 to 76 years with a
mean ± SD value of 49.88 ± 15.30 years, all patients were
current or former smokers and the pack year index ranged
from 20 to 66 with a mean ± SD value of 41.16 ± 13.80. Ta-
ble 1 shows the arterial blood gases, spirometric data and
acoustic analysis of voice.e 1 The arterial blood gases, spirometric data and
stic analysis of voice.
Minimum Maximum Mean SD
7.38 7.43 7.41 0.01
87 95 91.21 2.45
2 44 50 46.32 1.76
3 24 29.32 27.44 2.08
94 97 96.04 1.06
53 88 73.580 10.012
1 50 84 69.360 10.203
1/FVC 44 87 65.280 11.842
EF 43 80 64.560 11.172
age F0 100.65 125.43 115.987 7.598
% 0.02 1.98 1.157 0.616
mer% 0.21 1.98 1.260 0.564
: forced vital capacity, FEV1: forced expiratory volume after
rst second, FEV1/FVC: forced expiratory volume after the
second/forced vital capacity and MMEF: maximum mid
atory ﬂow. Average F0: fundamental frequency.Dysphonia was perceived in 25 (50%) patients. Endoscop-
ically, eight patients had bilateral hyperaemia and inﬂamma-
tion of the vocal folds (Fig. 1) and 3 patients had bilateral
reinke’s edema (Fig. 2). The most common predisposing factor
of reinke’s edema is smoking.
Table 2 shows signiﬁcant positive correlation between the
smoking index with Jitter%, Shimmer% and the grade of dys-
phonia (p= 0.000) and signiﬁcant inverse correlation between
the smoking index with fundamental frequency (p= 0.001).Figure 2 Bilateral reinke’s edema.
Table 2 Correlation between the smoking
index with the fundamental frequency, Jitter%,
Shimmer% and the degree of dysphonia.
Smoking index
Average F0 r= 0.930
p= 0.001*
Jitter% r= 0.930
p= 0.000*
Shimmer% r= 0.931
p= 0.000*
Grade of dysphonia r= 0.966
p= 0.000*
Average F0: fundamental frequency.
* Signiﬁcant correlation.
Table 4 Correlation between the pressurized metered dose
inhalers usage and the dry powder inhalers usage with the
fundamental frequency, Jitter%, Shimmer% and the degree of
dysphonia.
pMDIs usage DPIs usage
Average F0 r= 0.684 r= 0.684
p= 0.003* p= 0.001*
Jitter% r= 0.811 r= 0.811
p= 0.004* p= 0.000*
Shimmer% r= 0.886 r= 0.886
p= 0.003* p= 0.002*
Grade of dysphonia r= 0.878 r= 0.878
p= 0.000* p= 0.001*
Average F0: fundamental frequency.
pMDIs: pressurized metered dose inhalers.
DPIs: dry powder inhalers.
* Signiﬁcant correlation.
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Jitter%, Shimmer% and the grade of dysphonia with the small
to moderate doses of ICSs usage (p= 0.004, 0.002 and 0.000)
respectively and signiﬁcant positive correlation between funda-
mental frequency with the small to moderate doses of ICSs
usage (p= 0.001). In addition, there was signiﬁcant positive
correlation between Jitter%, Shimmer% and the grade of
dysphonia with the large doses of ICSs usage (p= 0.000,
0.003 and 0.002) respectively and signiﬁcant inverse correlation
between fundamental frequency with the large doses of ICSs
usage (p= 0.003).
Table 4 demonstrates signiﬁcant positive correlation be-
tween Jitter%, Shimmer% and the grade of dysphonia with
pMDIs usage (p= 0.004, 0.003 and 0.000) respectively and
signiﬁcant inverse correlation between fundamental frequency
with pMDIs usage (p= 0.003). Moreover, there was signiﬁ-
cant inverse correlation between Jitter%, Shimmer% and the
grade of dysphonia with DPIs usage (p= 0.000, 0.002 and
0.001) respectively and signiﬁcant positive correlation between
fundamental frequency with DPIs usage (p= 0.001).
Table 5 shows signiﬁcant inverse correlation between FVC,
FEV1 and MMEF% of predicted values with Jitter%, Shim-
mer% and the grade of dysphonia and signiﬁcant positive cor-
relation between FVC, FEV1 and MMEF% of predicted
values with fundamental frequency.
Discussion
The voice problems can vary between patients depending on
co-morbidities, prescribed medications and severity of COPD.
Hoarseness is often present in COPD secondary to Gastro-
esophageal Reﬂux Disease (GERD). Up to 80% of COPD pa-
tients present with symptoms associated with GERD. The
acidic content of the reﬂuxed material causes changes to the
mucosal layer of the laryngeal tissue, including the true vocal
folds, resulting in a change in vocal quality [21]. Effects of long
term smoking which could contribute to changes in voice qual-
ity and pitch variation, upper respiratory tract infections, vocal
abuse, and laryngeal cancer, could also cause hoarseness [22].
Xerostomia or dry mouth can also be related to vocal
hoarseness. The presence of dry mouth, and therefore hoarse
vocal quality, can commonly be attributed to inhaled cortico-
steroids or mouth breathing. The side effects associated with
inhaled steroids may be due to inﬂammation or irritation of
the oropharyngeal and laryngeal mucosa, caused by residueTable 3 Correlation between the small to moderate doses
inhaled corticosteroids usage with the fundamental frequenc
Small to moderate doses of inhaled cortico
Average F0 r= 0.684
p= 0.001*
Jitter% r= 0.811
p= 0.004*
Shimmer% r= 0.886
p= 0.002*
Grade of dysphonia r= 0.878
p= 0.000*
Average F0: fundamental frequency.
* Signiﬁcant correlation.from the inhaled substance, oropharyngeal candidiasis and ste-
roid-induced vocal cord myopathy. Increased hoarseness,
rough voice, and loss of speech volume were reported in pa-
tients on higher doses of inhaled steroids [23].
In this study dysphonia was identiﬁed by high Jitter%,
Shimmer% and grade of dysphonia and low fundamental fre-
quency (average F0). There was signiﬁcant positive correlation
between the smoking index with Jitter%, Shimmer% and the
grade of dysphonia (p= 0.000) and signiﬁcant inverse correla-
tion between the smoking index with fundamental frequency
(p= 0.001).
Smoking may result in a far more dramatic loss of lung
function and dysphonia. The tobacco-associated hoarseness
can arise from disease of the larynx or vocal cords, either
inﬂammation or tumor growth. Matsuo et al. [24] found that
hoarseness in tobacco smokers is associated with an increased
frequency of polypoid vocal fold lesions and head and neck
cancer. Other study reported the acute and chronic effects of
cigarette smoke on oropharyngeal function; Dua et al. [25]
compared pharyngo-upper-esophageal sphincter contractile
reﬂexes in 10 healthy smokers and 10 healthy non-smokers,
and showed that smokers had an increased threshold required
for the initiation of the pharyngo-upper-esophageal sphincter
contractile reﬂex and high prevalence of GERD, micro-aspira-
tion and hoarseness.of inhaled corticosteroids usage and the high doses of
y, Jitter%, Shimmer% and the degree of dysphonia.
steroids usage High doses of inhaled corticosteroids usage
r= 0.651
p= 0.003*
r= 0.684
p= 0.000*
r= 0.659
p= 0.003*
r= 0.664
p= 0.002*
Table 5 Correlation between the spirometric data of the patients with the fundamental frequency, Jitter%, Shimmer% and the degree
of dysphonia.
FVC FEV1 FEV1/FVC MMEF
Average F0 r= 0.738 r= 0.723 r= 0.733 r= 0.723
p= 0.001* p= 0.000* p= 0.003* p= 0.000*
Jitter% r= 0.792 r= 0.856 r= 0.864 r= 0.837
p= 0.000* p= 0.003* p= 0.004* p= 0.002*
Shimmer% r= 0.840 r= 0.915 r= 0.919 r= 0.891
p= 0.005* p= 0.001* p= 0.000* p= 0.000*
Grade of dysphonia r= 0.828 r= 0.890 r= 0.833 r= 0.863
p= 0.004* p= 0.000* p= 0.000* p= 0.003*
Average F0: fundamental frequency.
FVC: forced vital capacity, FEV1: forced expiratory volume after the ﬁrst second, FEV1/FVC: forced expiratory volume after the ﬁrst second/
forced vital capacity and MMEF: maximum mid expiratory ﬂow.
* Signiﬁcant correlation.
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secondary to cigarette-smoke induced chronic sinusitis [22].
The frequent use of ICSs, especially at higher doses, has
been accompanied by concern about both systemic and local
side effects. The systemic complications of ICSs have been
extensively studied and are well-documented in the literature.
There are comparatively few studies reporting on the local
complications of ICSs. Compared with systemic side effects,
the local side effects of ICSs are considered to constitute infre-
quent and minor problems. However, while not usually seri-
ous, these local side effects are of clinical importance.
In this study there was signiﬁcant inverse correlation be-
tween Jitter%, Shimmer% and the grade of dysphonia with
the small to moderate doses of ICSs usage (p= 0.004, 0.002
and 0.000) respectively and signiﬁcant positive correlation be-
tween fundamental frequency with the small to moderate doses
of ICSs usage (p= 0.001). In addition, there was signiﬁcant
positive correlation between Jitter%, Shimmer% and the
grade of dysphonia with the large doses of ICSs usage
(p= 0.000, 0.003 and 0.002) respectively and signiﬁcant in-
verse correlation between fundamental frequency with the
large doses of ICSs usage (p= 0.003).
However, the anti-inﬂammatory steroid preparation would
cause inﬂammation in the upper airway, the problem is prob-
ably multifactorial, depending on the following factors: the ste-
roid (e.g., preparation, carrier substance, dose of steroid, and
regime), the manner in which it is propelled into the airways
(i.e., the inhaler device), intrinsic inﬂammation of the upper
airway in COPD patients, mechanical irritation because of
cough, inﬂammatory disease (e.g., rhinitis and postnasal cat-
arrh) and inﬂammatory stimuli (e.g., smoking and noxious
agents in the workplace).
Williamson et al. [10] reported dysphonia in 58% of pa-
tients using pressurized aerosol ICS preparations, compared
with 13% of controls. In 2000, Lavy et al. [26] conﬁrmed dys-
phonia via videostrobolaryngoscopy in 58% of patients who
were receiving ICS therapy. Rachelefsky et al. [27] analyzed
data from 23 studies published from 1966 through 2004 and
determined that, compared with placebo, ICS at all dosages
was associated with a 5.2-fold greater risk of dysphonia.
The wide range of incidence rates in these studies likely was
due to methodologic factors, dosage variability and how
the diagnosis was made, which included self-reported question-
naires, telephone surveys, clinical diagnoses, endoscopicexaminations, and histologic analyses of biopsy samples. Bear-
ing in mind the limitations of the described studies, we believe
that dysphonia caused by ICS therapy is not rare and should
be considered a frequent cause of dysphonia.
Causes of dysphonia associated with ICS therapy have been
poorly investigated, and the origins of dysphonia may have
multiple confounding factors. Williams et al. [28] identiﬁed
bowing in the vocal folds and proposed a possible association
between dysphonia and ICS therapy. Subsequently, they pos-
tulated that this bowing was due to a bilateral adductor myop-
athy induced by local deposition of topical corticosteroids.
Lavy et al. [26] described 22 patients with ICS-associated
dysphonia who underwent videostrobolaryngoscopy and an
objective acoustic analysis. Seventeen of the 22 were affected
by dysphonia on a daily basis: 9 had some evidence of poor vo-
cal fold apposition, and supraglottic hyperfunction was identi-
ﬁed in 8. Mucosal quality abnormalities were identiﬁed in 13
patients. The mucosal wave was difﬁcult to evaluate; however,
the authors identiﬁed 2 patients with mucosal wave asyn-
chrony. The individual analysis found no correlation between
the degree of vocal cord apposition and the speech evaluation
ﬁndings. The authors suggested that atrophy with bowing was
not likely the primary cause of dysphonia. Although they
noted that the primary cause was difﬁcult to establish because
of various ﬁndings, they maintained that corticosteroids had a
direct effect on the mucosa or on the mucus secreting glands of
the ventricles or the trachea.
The use of ICS predisposes to the development of an
inﬂammatory inﬁltrate; however, this does not necessarily have
a clinical correlate. In a prospective observational study of 50
patients, 18 more inﬂammatory inﬁltrate was identiﬁed in ICS
users compared with nonusers; however, pharyngeal erythema
was not correlated with an inﬂammatory inﬁltrate. Dysphonia
associated with ICS use likely results from deposition of active
ICS in the oropharynx during administration of the medica-
tion, so that a speciﬁc cause or mechanism of this disorder
has not yet been elucidated [29].
In this study there was signiﬁcant positive correlation be-
tween Jitter%, Shimmer% and the grade of dysphonia with
pMDIs usage (p= 0.004, 0.003 and 0.000) respectively and
signiﬁcant inverse correlation between fundamental frequency
with pMDIs usage (p= 0.003). Moreover, there was signiﬁ-
cant inverse correlation between Jitter%, Shimmer% and the
grade of dysphonia with DPIs usage (p= 0.000, 0.002 and
566 E.E. Mohamed, R.A. El maghraby0.001) respectively and signiﬁcant positive correlation between
fundamental frequency with DPIs usage (p= 0.001).
Dysphonia may be affected by the method used to admin-
ister medication. Selroos et al. [12] described 154 patients who
received ICS therapy for 2 years via an MDI and then switched
to administration via a DPI. They noted that the frequency of
dysphonia decreased from 21% to 6%. This change may be
attributable to differences in vocal cord positioning when using
a DPI compared with an MDI.
The meta-analysis of randomized controlled trials by
Rachelefsky et al. [27] found that ICS MDI devices were asso-
ciated with a 5-fold greater risk of dysphonia when compared
with placebo MDI devices, whereas the ICS DPI devices had 3-
fold greater risk vs. placebo DPI devices.
As regard dysphonia in patients receiving combined corti-
costeroid and bronchodilator therapy, Mirza et al. [30] de-
scribed voice and laryngeal changes in 5 patients who
switched from corticosteroid and bronchodilator therapy
administered separately to concurrent administration. Most
patients had areas of hyperemia and a plaque pattern on the
surface mucosa. The combination therapy was stopped to as-
sess reversibility of the mucosal lesions. Twelve weeks after
stopping the combination therapy, patients underwent a laryn-
geal examination; 3 showed substantial improvement in le-
sions, and 2 seemed to have complete recovery. More
recently, a systematic review of randomized controlled trials
by Frois et al. [31] found no differences in dysphonia or other
local adverse effects when comparing ﬂuticasone or budeso-
nide combined with long-term bronchodilator therapy.
In a pMDI, the drug is dissolved or suspended in a propellant
under pressure, and, when activated, a valve system releases a
metered dose of the drug and propellant. The propellant pro-
vides the force to propel and disaggregate particles. pMDIs
may bemanually actuated or breath-actuated. They can be used
alone or in combination with various devices or adaptations
(e.g., spacers or extendedmouthpieces) designed to slow the aer-
osol cloud, reduce oropharyngeal deposition, and promote ease
of use. This reduces the need for coordination of actuation and
inhalation, making the device easier to use [32].
DPIs do not require propellants but rely on the patient’s
inspiratory effort to disperse the drug into small particles
and deliver it to the lungs. An inspiratory ﬂow rate of 30 L/
min is needed to work the most efﬁcient DPIs, and nearly all
adults can achieve this (adult average, 60 L/min), even when
wheezy [33].
Common problems include the inability to coordinate actu-
ation and inspiration precisely enough to use a pMDI, or the
inability to inhale forcefully enough when wheezy to use a DPI.
A dry powder inhaler containing both a long-acting musca-
rinic antagonist (LAMA) and long-acting beta agonist (LABA)
has been approved for use in COPD in the United States. The
combination was compared with each of the individual agents
and placebo in a 24-week randomized trial that included over
1500 subjects with COPD. The combination inhaler achieved
greater increases in pulmonary function and improved symp-
tom control compared with the individual agents and placebo.
Adverse local events like hoarseness were infrequent [34].
In this study there was signiﬁcant inverse correlation be-
tween FVC, FEV1 and MMEF% of predicted values with
Jitter%, Shimmer% and the grade of dysphonia and signiﬁ-
cant positive correlation between FVC, FEV1 and MMEF%
of predicted values with fundamental frequency.The quality of voice is depending on breath support. Even
subtle respiratory problems can lead to changes in voice. Aero-
dynamic measurements play a role in quantifying airﬂow dur-
ing respiration and phonation. Pulmonary function tests may
play a role in identifying subtle respiratory problems. Dyspho-
nia can be directly linked to the disturbances in airﬂow volume
and rate. The decreased lung volume associated with COPD
and the common breathlessness contribute to dysphonia and
reduce message length resulting in a decrease in vocalization
efﬁciency [22].
Hypoxia causes deep structural and durational changes of
voice and that the same degree of hypoxia associated with
mental activities during test performance causes deeper degra-
dation of voice structure. The soft phonation may be contrib-
uted to the narcotic effect of hypercapnia [35].
Laryngeal observation is the most common practical tech-
nique used in assessing all voice disorders to show muscle ten-
sion. Every instance of recent onset, persistent hoarseness
should be thoroughly evaluated; never ignored or attributed
to a benign cause. Persistent hoarseness must be taken seri-
ously as it may be a sign of serious disease [36].
In conclusion: Dysphonia (hoarseness) in COPD patients
is multifactorial. The voice problems can vary between
COPD patients depending on the severity of smoking, pre-
scribed medications, method used to administer medication
and disease severity. However, inhaled corticosteroids are
associated with an increased occurrence of dysphonia. Any
evaluation of dysphonia in COPD patient should consider
the use of ICS as an adverse effect includes a thorough exam-
ination of the larynx, and rule out vocal cord nodules, post
tussive trauma and gastroesophageal reﬂux. We should use
the lowest effective dose of ICS and patients should be
instructed to rinse the mouth after inhalation. Instructions
should be provided on the proper method of inhalation.
Successful analysis should depend on cooperation and collab-
oration among pulmonologists, voice care specialists, and
other laryngologists in the care of any COPD patient had
hoarseness of voice.
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